Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 12 studies | 30% ± 15% | |
peripheral blood | 12 studies | 26% ± 8% | |
kidney | 7 studies | 24% ± 4% | |
intestine | 7 studies | 27% ± 14% | |
eye | 7 studies | 29% ± 12% | |
brain | 7 studies | 28% ± 9% | |
lymph node | 5 studies | 26% ± 8% | |
liver | 5 studies | 28% ± 20% | |
uterus | 4 studies | 32% ± 12% | |
skin | 4 studies | 18% ± 4% | |
breast | 4 studies | 18% ± 2% | |
pancreas | 3 studies | 46% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 4812.74 | 2642 / 2642 | 100% | 172.83 | 705 / 705 |
esophagus | 100% | 5070.67 | 1445 / 1445 | 100% | 105.45 | 183 / 183 |
ovary | 100% | 4312.92 | 180 / 180 | 100% | 141.27 | 430 / 430 |
pancreas | 100% | 2105.29 | 328 / 328 | 100% | 110.56 | 178 / 178 |
thymus | 100% | 4083.88 | 653 / 653 | 100% | 134.94 | 605 / 605 |
uterus | 100% | 5254.88 | 170 / 170 | 100% | 148.82 | 459 / 459 |
skin | 100% | 4603.56 | 1808 / 1809 | 100% | 170.58 | 472 / 472 |
prostate | 100% | 4411.49 | 245 / 245 | 100% | 136.52 | 501 / 502 |
kidney | 100% | 3856.13 | 89 / 89 | 100% | 120.19 | 899 / 901 |
stomach | 100% | 3856.31 | 359 / 359 | 100% | 116.34 | 285 / 286 |
intestine | 100% | 4780.41 | 966 / 966 | 100% | 126.32 | 525 / 527 |
lung | 100% | 3512.38 | 577 / 578 | 100% | 122.36 | 1152 / 1155 |
adrenal gland | 100% | 4940.03 | 258 / 258 | 100% | 131.28 | 229 / 230 |
liver | 100% | 2294.39 | 225 / 226 | 100% | 94.58 | 406 / 406 |
breast | 100% | 4244.78 | 459 / 459 | 99% | 126.11 | 1112 / 1118 |
bladder | 100% | 5339.90 | 21 / 21 | 99% | 134.29 | 499 / 504 |
adipose | 100% | 4183.72 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4998.00 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 129.22 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 170.84 | 29 / 29 |
muscle | 100% | 4893.61 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3925.80 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 127.82 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 77.07 | 1 / 1 |
heart | 99% | 4081.39 | 850 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 2293.88 | 882 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_2000434 | Biological process | regulation of protein neddylation |
GO_0045116 | Biological process | protein neddylation |
GO_0000338 | Biological process | protein deneddylation |
GO_0008180 | Cellular component | COP9 signalosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0140492 | Molecular function | metal-dependent deubiquitinase activity |
GO_0008233 | Molecular function | peptidase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | COPS6 |
Protein name | COP9 signalosome complex subunit 6 COP9 signalosome subunit 6 COP9 signalosome complex subunit 6 (SGN6) (Signalosome subunit 6) (JAB1-containing signalosome subunit 6) (MOV34 homolog) (Vpr-interacting protein) (hVIP) |
Synonyms | CSN6 HVIP |
Description | FUNCTION: Component of the COP9 signalosome complex (CSN), a complex involved in various cellular and developmental processes. The CSN complex is an essential regulator of the ubiquitin (Ubl) conjugation pathway by mediating the deneddylation of the cullin subunits of SCF-type E3 ligase complexes, leading to decrease the Ubl ligase activity of SCF-type complexes such as SCF, CSA or DDB2. The complex is also involved in phosphorylation of p53/TP53, c-jun/JUN, IkappaBalpha/NFKBIA, ITPK1 and IRF8, possibly via its association with CK2 and PKD kinases. CSN-dependent phosphorylation of TP53 and JUN promotes and protects degradation by the Ubl system, respectively. Has some glucocorticoid receptor-responsive activity. Stabilizes COP1 through reducing COP1 auto-ubiquitination and decelerating COP1 turnover rate, hence regulates the ubiquitination of COP1 targets. . FUNCTION: Component of the COP9 signalosome complex (CSN), a complex involved in various cellular and developmental processes. . |
Accessions | ENST00000419210.1 ENST00000303904.8 E7EM64 H7C3T0 ENST00000426712.1 ENST00000418625.5 Q7L5N1 C9JQK5 |